JP2022526646A5 - - Google Patents

Info

Publication number
JP2022526646A5
JP2022526646A5 JP2021559793A JP2021559793A JP2022526646A5 JP 2022526646 A5 JP2022526646 A5 JP 2022526646A5 JP 2021559793 A JP2021559793 A JP 2021559793A JP 2021559793 A JP2021559793 A JP 2021559793A JP 2022526646 A5 JP2022526646 A5 JP 2022526646A5
Authority
JP
Japan
Prior art keywords
seq
cell line
nucleotide sequence
expression
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526646A (ja
JP7560475B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027489 external-priority patent/WO2020210507A1/en
Publication of JP2022526646A publication Critical patent/JP2022526646A/ja
Publication of JP2022526646A5 publication Critical patent/JP2022526646A5/ja
Priority to JP2024094278A priority Critical patent/JP7706607B2/ja
Application granted granted Critical
Publication of JP7560475B2 publication Critical patent/JP7560475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559793A 2019-04-12 2020-04-09 操作された産生細胞株ならびにそれを作製および使用する方法 Active JP7560475B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094278A JP7706607B2 (ja) 2019-04-12 2024-06-11 操作された産生細胞株ならびにそれを作製および使用する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962833548P 2019-04-12 2019-04-12
US62/833,548 2019-04-12
US201962839207P 2019-04-26 2019-04-26
US62/839,207 2019-04-26
US202062979483P 2020-02-21 2020-02-21
US62/979,483 2020-02-21
PCT/US2020/027489 WO2020210507A1 (en) 2019-04-12 2020-04-09 Engineered producer cell lines and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094278A Division JP7706607B2 (ja) 2019-04-12 2024-06-11 操作された産生細胞株ならびにそれを作製および使用する方法

Publications (3)

Publication Number Publication Date
JP2022526646A JP2022526646A (ja) 2022-05-25
JP2022526646A5 true JP2022526646A5 (cg-RX-API-DMAC7.html) 2023-04-17
JP7560475B2 JP7560475B2 (ja) 2024-10-02

Family

ID=70465550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559793A Active JP7560475B2 (ja) 2019-04-12 2020-04-09 操作された産生細胞株ならびにそれを作製および使用する方法
JP2024094278A Active JP7706607B2 (ja) 2019-04-12 2024-06-11 操作された産生細胞株ならびにそれを作製および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094278A Active JP7706607B2 (ja) 2019-04-12 2024-06-11 操作された産生細胞株ならびにそれを作製および使用する方法

Country Status (15)

Country Link
US (2) US12018288B2 (cg-RX-API-DMAC7.html)
EP (2) EP3953458A1 (cg-RX-API-DMAC7.html)
JP (2) JP7560475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210152514A (cg-RX-API-DMAC7.html)
CN (1) CN113966395B (cg-RX-API-DMAC7.html)
AU (1) AU2020270960B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020391A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136246A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021013699A2 (cg-RX-API-DMAC7.html)
IL (1) IL287106A (cg-RX-API-DMAC7.html)
MX (1) MX2021012489A (cg-RX-API-DMAC7.html)
PH (1) PH12021552577A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110904PA (cg-RX-API-DMAC7.html)
TW (1) TWI859216B (cg-RX-API-DMAC7.html)
WO (1) WO2020210507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12054738B2 (en) 2020-07-30 2024-08-06 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
JP2024531138A (ja) 2021-08-11 2024-08-29 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 筋ジストロフィーを処置するための組成物および方法
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
WO2023077078A1 (en) 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)
CA3245327A1 (en) 2022-03-07 2023-09-14 Ultragenyx Pharmaceutical Inc. MODIFIED BATCH-BASED AAV PRODUCTION SYSTEMS AND PROCESSES
CN122161940A (zh) * 2023-10-12 2026-06-05 塞维克制药有限责任公司 影响重组aav生产的细胞因子
WO2025226558A1 (en) 2024-04-22 2025-10-30 Ultragenyx Pharmaceutical Inc. Multi-step filtration and clarification methods for recombinant adeno-associated virus purification
WO2026078664A1 (en) 2024-10-10 2026-04-16 Instituto De Biologia Experimental E Tecnológica (Ibet) Transcription factor enhancing recombinant adeno-associated virus production, products, methods and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
WO2000024916A1 (en) 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ATE530667T1 (de) 2005-05-27 2011-11-15 Evotec Neurosciences Gmbh Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
PT3272872T (pt) 2005-10-20 2020-06-26 Uniqure Ip Bv Vetores aav melhorados produzidos em células de insetos
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
CN104592364B (zh) * 2013-10-30 2018-05-01 北京大学 定点突变和定点修饰的腺相关病毒、其制备方法及应用
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
US20160319277A1 (en) 2015-01-28 2016-11-03 The Johns Hopkins University METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs
ES2938833T3 (es) 2016-03-28 2023-04-17 Ultragenyx Pharmaceutical Inc Métodos de inactivación térmica de adenovirus
EP3484493A4 (en) 2016-07-12 2019-12-25 Ultragenyx Pharmaceutical Inc. USE OF GLUCOCORTICOID ANALOGS TO INCREASE THE PERFORMANCE OF RECOMBINANT ADENO-ASSOCIATED VIRUSES
ES3012649T3 (en) 2016-10-14 2025-04-09 Ultragenyx Pharmaceutical Inc Use of tonicifying agents to enhance recombinant adeno-associated virus yield
US20200048641A1 (en) 2017-03-22 2020-02-13 Ultragenyx Pharmaceutical Inc. Methods for enhancing yield of recombinant adeno-associated virus
EP3601581B1 (en) 2017-03-22 2025-04-30 Ultragenyx Pharmaceutical Inc. CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS
EP3621734A4 (en) 2017-05-09 2020-12-30 Ultragenyx Pharmaceutical Inc. MODULAR PROCESS FOR THE PRODUCTION OF TRANSFECTION REAGENTS
CA3088538A1 (en) 2018-01-19 2019-07-25 The University Of North Carolina At Chapel Hill Methods and compositions for inhibition of innate immune response associated with aav transduction
US12577539B2 (en) 2019-04-26 2026-03-17 The Regents Of The University Of California Cells for enhanced production of adeno-associated virus
WO2023077078A1 (en) * 2021-10-29 2023-05-04 Ultragenyx Pharmaceutical Inc. Engineered cell lines for increased production of recombinant adeno-associated virus (raav)

Similar Documents

Publication Publication Date Title
US12612643B2 (en) RNA-guided human genome engineering
CN109689677B (zh) 用于基因组编辑分子的细胞内递送的肽和纳米颗粒
Papolu et al. Retrotransposons: How the continuous evolutionary front shapes plant genomes for response to heat stress
Zhang et al. Amplification editing enables efficient and precise duplication of DNA from short sequence to megabase and chromosomal scale
JP2024107295A5 (cg-RX-API-DMAC7.html)
JP2018530336A5 (cg-RX-API-DMAC7.html)
US20250257342A1 (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
CN113966395B (zh) 工程化的生产细胞系及其制备和使用方法
JP2016521993A5 (cg-RX-API-DMAC7.html)
JP2022521787A5 (cg-RX-API-DMAC7.html)
Uniyal et al. The CRISPR–Cas9, genome editing approach: a promising tool for drafting defense strategy against begomoviruses including cotton leaf curl viruses
RU2021132765A (ru) Линии сконструированных клеток-продуцентов и способы их получения и применения
TH2101006399A (th) เซลล์ไลน์ผู้ผลิตที่ผ่านการทำวิศวกรรม และวิธีการสร้างและการใช้สิ่งเดียวกันนี้
US20250257340A1 (en) Guide nucleic acid identification and methods of use
US20250308637A1 (en) Systems and methods for assessing risk of genome editing events
US20250354177A1 (en) System and methods for duplicating target fragments
HK40064529A (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
HK40103974A (en) Rna-guided human genome engineering
Garazha et al. Structural and Functional Coevolution of Human Endogenous Retroviruses with Our Genome
WO2018223843A1 (zh) 用于dna编辑的系统及其应用
HK40014881A (en) Rna-guided human genome engineering
HK40006957B (en) Peptides and nanoparticles for intracellular delivery of genome-editing molecules
BR112018010429B1 (pt) Ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados, composição de ácido nucleico/proteína, e kit
HK1212376B (en) Rna-guided human genome engineering